Effect of One-Year Growth Hormone Therapy on Cardiometabolic Risk Factors in Boys with Obesity

Table 1

Subjects’ demographic and clinical characteristics.

Variable	Obese group (n = 18)	Control group (n = 18)	value
Age (year)	11.87 ± 1.43	11.53 ± 2.23	0.585
Puberty: yes	5 (18)	6 (18)	0.717
No	13 (18)	12 (18)
HT SDS	0.21 ± 0.82	0.28 ± 1.03	0.819
BMI SDS	2.38 ± 0.39	−0.17 ± 0.77	<0.001
Peak-stimulated GH (μg/L)	2.44 (1.49–4.24)	16.90 (11.23–18.48)	<0.001
IGF-1 (μg/ml)	243.44 ± 124.61	337.94 ± 114.52	0.024
TC (mmol/L)	4.53 ± 0.61	3.90 ± 0.57	0.003
HDL-C (mmol/L)	1.26 ± 0.24	1.56 ± 0.36	0.006
LDL-C (mmol/L)	2.76 ± 0.46	2.04 ± 0.37	<0.001
TG (mmol/L)	1.34 ± 0.65	0.61 ± 0.23	<0.001
ALT (U/L)	31.24 ± 21.85	13.67 ± 3.45	<0.001#
Insulin (μIU/mL)	24.34 ± 13.52	9.07 ± 5.29	<0.001#
C-peptide (μg/ml)	3.39 ± 1.28	1.81 ± 0.55	0.008
FBG (mmol/L)	5.24 ± 0.33	5.24 ± 0.37	0.955
HOMA-IR	5.67 ± 3.12	4.39 ± 0.90	<0.001#

# value reported for log-transformed values, but values in the table represent a back transformation to the original .